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Abstract 
Super agonists produce greater functional responses than endogenous agonists in the same 
assay, and their unique pharmacology is the subject of increasing interest and debate. We 
propose that receptor residence time and the duration of receptor signalling contributes to this 
newly described phenomenon of super agonism. We have further characterised the novel β2 
adrenoceptor agonist C26 (7-[(R)-2-((1R,2R)-2-benzyloxycyclopentylamino)-1-
hydroxyethyl]-4-hydroxybenzothiazolone), which displays higher intrinsic activity than the 
endogenous ligand adrenaline in cAMP accumulation, β-arrestin-2 recruitment and receptor 
internalization assays. C26 recruited β-arrestin-2, and internalized the GFP-β2 adrenoceptor 
at a slow rate, with t½ values of 0.78 ± 0.1 and 0.78 ± 0.04 hr, respectively. This was 
compared to 0.31 ± 0.04 and 0.34 ± 0.01 hr for adrenaline-mediated β-arrestin-2 recruitment 
and GFP-β2 internalization, respectively. The slower rate for C26 resulted in levels of β-
arrestin-2 recruitment increasing up to 4 hr agonist incubation, at which point the intrinsic 
activity was determined to be 124.3 ± 0.77 % of the adrenaline response. In addition to slow 
functional kinetics, C26 displayed high affinity with extremely slow receptor dissociation 
kinetics, giving a receptor residence half-life of 32.7 min at 37°C that represents the slowest 
dissociation rate we have observed for any β2 adrenoceptor agonist tested to date. In 
conclusion, we propose that the gradual accumulation of long-lived active receptor 
complexes contributes to the increased intrinsic activity of C26 over time. This highlights the 
need to consider the temporal aspects of agonist binding and signalling when characterising 
ligands as super agonists. 
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Introduction 
Inhaled long-actin β2 adrenoceptor agonists (LABA) e.g. formoterol and salmeterol, which 
have a duration of action of approximately 12 hours have been widely used for the treatment 
of chronic obstructive pulmonary disease (COPD), providing symptomatic relief by inducing 
bronchodilation via relaxation of airway smooth muscle. More recently, a further class of β2 
adrenoceptor agonists has been developed, termed ultra LABA (e.g. indacaterol) which have 
duration of action after a single inhaled dose of 24 hours. 7-[(R)-2-((1R,2R)-2-
benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone (from herein 
referred to as C26), was originally identified as a high affinity β2 adrenoceptor agonist with 
predicted long duration of action. In addition to its high affinity, in a human A431 cell lysate 
cAMP assay C26 exhibited greater potency and a higher intrinsic activity of 140 % compared 
to formoterol (Beattie et al., 2010). Here we have further characterised the pharmacological 
profile of C26 in both binding and functional assays in comparison to the endogenous β2 
adrenoceptor agonist adrenaline and its stable analogue isoprenaline. 
The binding of an agonist to a receptor produces a signalling cascade which leads to a variety 
of cellular, tissue and organ responses that can occur in a timescale of seconds to hours. 
However the initial receptor stimulation with agonist is often rapid and short lived, due 
mainly to desensitization of the receptor, which begins within seconds of agonist exposure 
and is initiated by phosphorylation of the receptor and ultimately leads to its internalization. 
In general, endogenous agonists of G protein-coupled receptors (GPCR), such as adrenaline 
for the β2 adrenoceptor, have low affinity but high efficacy meaning that few receptors need 
to be activated to achieve a maximum response. In addition, although a limited number of 
agonists have been studied to date, they also appear to rapidly dissociate from the receptor 
(Sykes and Charlton, 2012) thus reducing the risk of persistent signalling and over-
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stimulation of a pathway which may be detrimental to the cell or organism, and allowing 
rapid re-setting of the system.  
It is generally assumed that the interaction between an endogenous agonist and its receptor, 
as a result of strong evolutionary pressure, is likely to be as efficient as it can possibly be. If 
such a case were true, the maximal asymptote of the concentration-response curves of 
endogenous agonists, fitted to experimental data (Strange, 2008) (intrinsic activity, Emax), 
would always be equal to the system maximum. However, there are a class of synthetic 
ligands such as MK-677 at the GNRH receptor or R-Des-TRH at the TRH receptor (Bennett 
et al., 2009; Engel et al., 2006) that have been demonstrated to produce higher maximal 
responses than their respective endogenous ligands, leading to the term super agonist being 
coined. Such terminology has been met with mixed views in the pharmacology community, 
and the unique pharmacology of super agonists is now the subject of increasing interest and 
debate.  
Evidence from structural studies on the β2 adrenoceptor (Nygaard et al., 2013) demonstrated 
that the change in conformation upon activation of a receptor depends as much upon the 
presence of G protein as it does on agonist, such that agonist binding alone is not able to 
stabilize a fully active receptor conformation. The ‘mobile’ or ‘fluid’ receptor hypothesis 
describes the active receptor complex as having three entities, receptor, effector and ligand, 
that are able to interact in a cooperative manner (de Haën, 1976; Jacobs and Cuatrecasas, 
1976). In simplest terms, a high efficacy ligand will therefore act as a positive allosteric 
modulator, increasing the association of the effector protein with the receptor. As allosteric 
interactions are reciprocal, it also follows that association of the effector molecule with the 
receptor can be considered to exert positive allosteric modulation of ligand binding. 
Conversely, dissociation of effector (or association of inactive effector complex) could be 
considered to negatively regulate ligand binding, thus reducing its affinity for the receptor. 
MOL #101253 
6 
 
One could therefore speculate that even the fully efficacious endogenous agonists may not be 
able to maximally activate receptors in cellular systems where high levels of cytosolic 
guanine nucleotides uncouple the receptor from G proteins and drive it away from the active 
state (Ehlert, 2008), thus leaving scope for ‘super agonism’ to occur. 
In this study we have used a number of functional and binding assay systems to fully 
characterize the pharmacology of C26. We will demonstrate that C26 displays interesting 
pharmacological properties, as it shares binding characteristics with low efficacy partial 
agonists, but appears in functional assays to be a kinetically-driven super agonist in terms of 
its intrinsic activity. 
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Materials and Methods 
Materials 
PathHunter™ cell lines, lysis and Flash detection reagents were purchased from DiscoveRx 
(Birmingham, UK). CO2-indepenent medium, DMEM supplemented with 4.5g/L D-Glucose, 
L-Glutamine and pyruvate, Hams F12 media supplemented with GlutaMAX, McCoys 5A 
media, heat inactivated foetal bovine serum (FBS), geneticin, hygromycin, blasticidin, 
penicillin, streptomycin, trypsin-EDTA, Dulbecco’s phosphate buffered saline solution 
(DPBS), Hank’s balanced salt solution without phenol red (HBSS w/o phenol red) and 
HEPES were all purchased from Life Technologies (Paisley, UK). ALPHAScreen cAMP 
detection kit, [3H]-DHA and 384- and 96-well Viewplates™ were purchased from Perkin 
Elmer Life Sciences (Massachusetts, USA).  GloSensor cAMP reagent and GloSensor cAMP 
plasmid were purchased from Promega (Hampshire, UK). Bovine serum albumin (BSA), 
Tween-20, adrenaline (epinephrine), isoprenaline, DMSO, GTP and ascorbic acid, were 
purchased from Sigma Aldrich (Poole, UK). C26 was synthesized in-house (Beattie et al., 
2010).   
Cell culture 
A431 cells (human carcinoma cell line; Life Technologies, UK) were maintained in DMEM 
supplemented with 4.5g/L D-Glucose, L-Glutamine, pyruvate and FBS (10 % v/v). 
PathHunter™ CHO-K1 human β2 adrenoceptor:β-arrestin-2 cells (CHO-arrestin-β2) were 
maintained in Hams F12 nutrient mix supplemented with FBS (10 % v/v), hygromycin B (0.2 
mg/mL) and Geneticin (0.5 mg/mL). Chinese hamster ovary cells stably transfected with the 
human β2 adrenoceptor (CHO-β2) prepared in-house, were maintained in Hams F-12 Nutrient 
Mix GlutaMAX-1, supplemented with FBS (10 % v/v) and geneticin (0.5 mg/mL). U2OS 
cells stably transfected with GFP tagged human β2 adrenoceptor (U2OS-GFP-β2) prepared in 
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house (Rosethorne et al., 2015), were maintained in McCoys 5A media supplemented with 
FBS (10 % v/v) and geneticin (0.5 mg/mL). All cells were grown adherently and maintained 
at 37°C in 5 % CO2/humidified air. For routine culture and for experiments all of the cells 
were harvested using trypsin/EDTA. For radioligand binding studies, membranes were 
prepared from CHO-β2 cells as described in Sykes et al., (2009). 
Measurement of cAMP using A431 cells endogenously expressing human β2-
adrencoceptor 
A431 cells were seeded overnight in white, 96-well ViewPlates™ at 20,000 cells/well in 
culture medium. Spent media was removed and replaced with assay buffer (HBSS w/o phenol 
red, 5 mM HEPES and 0.1 % (v/v) BSA). Cells were then stimulated with a range of 
concentrations of agonist for 1 hr at room temperature. The incubation was terminated by the 
addition of lysis buffer (dH2O, 0.3 % (v/v) Tween-20) containing 20 units/mL streptavidin 
coated donor beads, biotinylated cAMP and anti-cAMP acceptor beads. A cAMP standard 
curve (10,000 nM to 0.001 nM) was constructed in each experiment, and lysis buffer 
containing the bead mix was added to the standard curve at the same time it was added to the 
wells of the assay. The assay plate and standard curve plate were incubated in the dark, 
overnight at room temperature. The plate was then read on the EnVision plate reader (Perkin 
Elmer Life Sciences; Massachusetts, USA). The levels of cAMP produced were always 
within the linear part of the standard curve. For time course experiments, A431 cells were 
transiently transfected with the GloSensor cAMP plasmid, using Lipofectamine2000 
according to manufacturers’ instructions. 24 hours later, cells were stimulated with a range of 
concentrations of each agonist and luminescence monitored over time (every minute for 25 
minutes). Responses were obtained for an EC80 concentration of isoprenaline (32 nM) and 
equi-effective concentrations of C26 (0.3 nM) and adrenaline (63 nM) (concentrations of C26 
and adrenaline which produce the same amount of cAMP as the EC80 concentration of 
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isoprenaline after 8 minute treatment in this assay). To account for the inter-assay variation in 
levels of cAMP which were produced in each experiment, data were normalized to the 
amount of cAMP produced compared to the maximum isoprenaline response. 
Measuring β-arrestin-2 recruitment to the human β2 adrenoceptor in CHO-arrestin-β2 
cells  
β-arrestin-2 recruitment was monitored using an enzyme-fragment complementation assay 
(DiscoveRx, Birmingham, UK). CHO-arrestin-β2 cells were seeded overnight in white, 384-
well ViewPlates at 10,000 cells/well in culture medium. Spent media was removed and 
replaced with assay buffer (HBSS supplemented with 10 mM HEPES, 0.1 % (w/v) BSA). 
Cells were then stimulated with a range of concentrations of agonist for 2 hr at 37°C, after 
which time Flash detection reagent was added and luminescence read on the EnVision plate 
reader. In addition, time courses of β-arrestin-2 recruitment were performed, whereby a range 
of concentrations of each agonist was added to the cells and Flash detection reagent added at 
different times from 0 – 4 hr. To construct association curves, responses obtained for an EC80 
concentration of isoprenaline (13.5 nM) and equi-effective concentrations of C26 (0.29 nM) 
and adrenaline (110 nM). To account for the inter-assay variation in levels of luminescence 
produced in each experiment, data were normalized to the maximum isoprenaline response. 
 
Measuring human β2 adrenoceptor internalization using U2OS-GFP-β2 cells 
U2OS-GFP-β2 cells were seeded overnight in black, 384-well ViewPlates at 3,000 cells/well 
in culture medium. Spent media was removed and replaced with cell culture medium 
containing 100 mg/mL cycloheximide to inhibit protein biosysnthesis and generation of new 
receptors inside the cell. After 4 hr, the cycloheximide-containing medium was replaced with 
assay buffer (CO2-independent medium supplemented with 5 mM HEPES, 0.01 % w/v 
MOL #101253 
10 
 
ascorbic acid, 0.05 % w/v HSA and 100 mg/mL cycloheximide) containing 1 µM Hoechst to 
label nuclei. Cells were then stimulated with a range of concentrations of agonist for 2 hr at 
37°C, after which time receptor internalization was quantified on the InCell Analyzer 2000 
(GE Healthcare; Buckinghamshire, UK) using DAPI settings to visualize nuclei (5 ms 
exposure) and FITC settings for GFP (200 ms exposure). All images were collected using a 
Nikon 20x 0.45 NA objective and a large chip CCD camera (2048x2048 pixel). In addition, 
time courses of receptor internalization were performed, whereby an EC80 concentration of 
isoprenaline, as determined in this assay at 2 hr (80 nM), and an equi-effective concentration 
of C26 (0.2 nM) and adrenaline (300 nM) were added to the cells and receptor internalization 
monitored on the InCell Analyzer 2000 every 5 min for 2 hr, using the settings above. For 
agonist wash-out studies, cells were first imaged to enable monitoring of baseline levels of 
internalized receptors, incubated with EC80 concentrations of agonist (see above) for 2 hr at 
37°C, and imaged again prior to washing 5 times in fresh assay buffer using an automated 
Biomek FX (Beckman Coulter; High Wycombe, UK) and fresh tips for each washout step. 
Following agonist washout, the assay plate was imaged on the InCell Analyzer 2000 every 5 
min for 4 hr, using the settings above. Cellular image analysis was performed using the IN 
Cell Analyzer Workstation 3.7.1 (GE Healthcare; Buckinghamshire, UK) to measure the 
presence of vesicles (1 – 3 μm) containing the GFP-tagged β2 adrenoceptor. To account for 
the inter-assay variation in levels of fluorescence produced in each experiment, data were 
normalized to the maximum isoprenaline response. 
Common procedures applicable to all radioligand binding experiments 
All radioligand experiments were conducted in 96 deep well plates. In all cases non-specific 
binding (NSB) was determined in the presence of 1 μM propranolol. After the indicated 
incubation period, bound and free radiolabel were separated by rapid vacuum filtration using 
a FilterMateTM Cell Harvester (Perkin Elmer Life Sciences; Massachusetts, USA) onto 96 
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well GF/B filter plates and rapidly washed three times with ice cold HEPES (75 mM, pH 
7.4). After drying (>4 hr), 40 µL of MicroscintTM 20 (Perkin Elmer Life Sciences; 
Massachusetts, USA) was added to each well and radioactivity quantified using single photon 
counting on a TopCountTM microplate scintillation counter (Perkin Elmer Life Sciences; 
Massachusetts, USA). Aliquots of radiolabel were also quantified, to accurately determine 
how much radioactivity was added to each well, using liquid scintillation spectrometry on LS 
6500 scintillation counter (Beckman Coulter; High Wycombe, UK). In all experiments, total 
binding never exceeded more than 10 % of that added, limiting complications associated with 
depletion of the free radioligand concentration (Scaramellini Carter, 2007). 
Determination of agonist affinity (Ki) 
Affinity estimates of unlabelled agonists were determined using two slightly different assay 
formats depending on whether the Ki determined was to be used in competition kinetic 
experiments or whether it was to be used to investigate GTP sensitivity. In each case, [3H]-
DHA competition experiments were performed at equilibrium and [3H]-DHA was used at a 
concentration of approximately 600 pM (~25000 cpm final assay volume of 1.5 mL). 
Radioligand was incubated in the presence of the indicated concentration of unlabelled 
agonist and CHO-β2 membranes (30 μg/ml) with gentle agitation for 180 min. Ki values 
determined for kinetic experiments were performed in binding buffer (HBSS supplemented 
with 20 mM HEPES, 0.1 % w/v BSA, 5 % v/v DMSO, 0.01 % w/v ascorbic acid and 100 µM 
GTP) and experiments were run at 37°C. Ki values determined to investigate GTP sensitivity 
were performed in assay buffer (20 mM HEPES, 1 mM MgCl2, 0.1 % w/v BSA, 5 % v/v 
DMSO and 0.01 % w/v ascorbic acid) ± 30 μM GTPγS and the experiments were run at room 
temperature. 
Competition binding kinetics 
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To accurately determine kon and koff values, the Kob was calculated for at least three different 
concentrations of [3H]-DHA in binding buffer. The appropriate concentration of radioligand 
was incubated with CHO-β2 membranes (30 μg/ well) in binding buffer with gentle agitation 
(final assay volume 1000 μL). Exact concentrations were calculated in each experiment by 
liquid scintillation counting. Free radioligand was separated by rapid filtration at multiple 
time points to construct association kinetic curves, and the resulting data were globally fitted 
to the association kinetic model to derive a single best fit estimate for kon and koff as described 
previously by Sykes et al., (2009). 
The kinetic parameters of C26 were assessed using a competition kinetic binding assay as 
described by Sykes et al., (2009) in binding buffer. This approach involves the simultaneous 
addition of both radioligand and competitor to receptor preparation, so that at t=0 all 
receptors are unoccupied. Approximately 600 pM [3H]-DHA (a concentration which avoids 
ligand depletion in this assay volume) was added simultaneously with the unlabelled 
compound (at t=0) to CHO-β2 membranes (30 μg/well) in 500 μl binding buffer. The degree 
of [3H]-DHA bound to the receptor was assessed at multiple time points by filtration 
harvesting and liquid scintillation counting, as described previously. NSB was subtracted 
from each time point meaning that t = 0 was always equal to 0. Each time point was 
conducted on the same 96-deep well plate incubated at 37°C with constant agitation. 
Reactions were considered stopped once the membranes reached the filter, and the first wash 
was applied within 1 sec. Three different concentrations of unlabelled competitor were tested 
to ensure the rate parameters calculated were independent of ligand concentration. All 
compounds were tested at 30, 10, and 3-fold their respective Ki and data were globally fitted 
to simultaneously calculate kon and koff. 
Measuring inhibition of contraction of isolated guinea pig tracheal strips 
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Male Dunkin-Hartley guinea pigs (350–700 g Charles River Margate, UK) were killed by 
exposure to an increasing concentration of CO2; the trachea was removed and placed in 
oxygenated (95 % O2/5 % CO2) Krebs-Henseleit solution (118 mM NaCl, 25 mM NaHCO3, 
11.1 mM glucose, 4.8 mM KCl, 205 mM CaCl2, 1.2 mM MgSO4, 1.2 mM Na2PO4, 1.2 mM 
KH2PO4). The method used for the electrically-stimulated tracheal strip is a modification of 
a previously published technique (Coleman and Nials, 1989). The trachea was cut into rings 
of 4-5 cartilage bands in width, which were subsequently opened into strips by cutting the 
cartilage opposite the smooth muscle band in order to create a strip with equal lengths of 
trachea each side of the muscle band. Each strip was set up in a superfusion system and 
attached to an isometric force transducer (Fort 10, World Precision Instruments, Stevenage, 
Hertfordshire, UK) under a resting tension of 1 g and superfused (1 mL/min) with 
oxygenated Krebs-Henseleit solution at 37°C. Following a 1 hr equilibration period, phasic 
contractile responses were induced by electrical stimulation with 5 sec trains of square wave 
pulses of 10 volt, 10 Hz frequency and 0.2 ms duration every 2 min. After a 1 hr equilibration 
period using the above stimulation parameters, a baseline contractile response was 
determined over a 20 min period before the superfusion fluid was changed to Krebs-Henseleit 
solution containing C26 for 30 min. After this time, the superfusion fluid was changed back 
to compound-free Krebs-Henseleit solution for the remaining 11.5 hr of the experiment.  
The onset of action of guinea pig tracheal contraction to electrical stimulation for each 
concentration of C26 was taken as the time from the start of compound superfusion until 
maximum inhibition of contraction to electrical stimulation was observed. The duration of 
action was defined as the time taken from the end of compound superfusion to 50 % recovery 
from maximum inhibition. The percentage maximum inhibition at each concentration of C26 
was used to construct a concentration-response curve to calculate potency. 
Data analysis 
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All experiments were analysed by either linear or non-linear regression using Prism 6.0 
(GraphPad Software, San Diego, U.S.A.). Competition displacement binding data and agonist 
concentration effect curves were fitted to sigmoidal (variable slope) curves using a four 
parameter logistic equation. IC50 values obtained from the inhibition curves were converted 
to Ki values using the method of Cheng and Prusoff (1973).  
To monitor the rate of cAMP accumulation, the area under the curve (AUC) was fitted to the 
data for the initial 10 minutes of accumulation. To calculate the rate of β-arrestin-2 
recruitment and GFP-β2 internalization, data were analysed using non-linear regression, one 
phase exponential association to determine the rate constant K. The rate half-time was then 
calculated as 0.69/K. Statistical significance was determined using one-way ANOVA 
followed by Bonferroni multiple comparisons equation using GraphPad Prism, comparing 
C26 and isoprenaline to adrenaline.   
For washout experiments, the data were normalised to pre-wash levels of internalized 
receptors and the plateau fixed to zero for all agonists. Data were analyzed using non-linear 
regression, one phase exponential decay to determine the rate constant K, and the rate half-
time was calculated as 0.69/K. Statistical significance was determined using one-way 
ANOVA followed by Bonferroni multiple comparisons equation using GraphPad Prism. 
Because the amount of radioactivity varied slightly for each experiment (< 5%), data are 
shown graphically as the mean ± range for individual representative experiments, whereas all 
values reported in the text and tables are mean ± S.E.M. for the indicated number of 
experiments. [3H]-DHA association data were globally fitted in GraphPad Prism to determine 
a best fit estimate for kon and koff. Association and dissociation rates for unlabelled agonists 
were calculated using the equations described by Motulsky and Mahan (1984) using a global 
fitting model (see Sykes et al., (2009) for details). 
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To evaluate the relative efficacy of agonists, data were fitted to the operational model of 
Black and Leff (1983). This model describes the correlation between biological response and 
agonist concentration [A] as a function of four parameters: Em, KA n and τ: 
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where Em, or the operational maximum, represents the maximum possible effect in the tissue 
and n represents the transduction slope . KA is the dissociation constant of the agonist and τ is 
the operational efficacy or the transducer ratio. When this equation was applied to data, [A] 
was varied according to experimental design, KA was fixed to the value obtained in 
competition binding assays and Em was globally fitted across all data sets, leaving n and τ as 
the only terms fitted individually for each agonist. 
In addition, we used the following equations to calculate alternative values for agonist 
efficacy using experimental data from cAMP accumulation, β-arrestin-2 recruitment and β2 
adrenoceptor internalization (Strange, 2008): 
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Results 
Functional characterization of C26 
We have previously reported that a novel 4-hydroxybenzothiazolone series of β2 
adrenoceptor agonists have both high potency and increased relative intrinsic activity 
compared to formoterol, in a cAMP assay using A431 cell lysates (Beattie et al., 2010). We 
re-visited this assay specifically to investigate the relative intrinsic activity of C26 (figure 1) 
with respect to the endogenous agonist adrenaline, in addition to the more stable full agonist 
isoprenaline, in whole cells.  
Isoprenaline and adrenaline showed comparable potency and efficacy values in these cells, 
whereas C26 was almost 500-fold more potent in the cAMP assay. We were able to confirm 
that C26 does indeed have higher intrinsic activity with respect to adrenaline and 
isoprenaline, giving 117.8 ± 7.6 % of the isoprenaline response (p = 0.034, one-way ANOVA 
followed by Bonferroni post-test) (figure 2a; table 1). In addition, C26, adrenaline and 
isoprenaline were able to recruit β-arrestin-2 and cause GFP-β2-adrenoceptor internalization 
in a concentration-dependent manner (figure 2b, c; table 1). In both assays, C26 also 
demonstrated greater intrinsic activity compared to adrenaline and isoprenaline, with Emax of 
119 ± 6.7 (P = 0.027) and 121 ± 6.9 % (P = 0.0021) of the maximal isoprenaline response 
(one-way ANOVA followed by Bonferroni post-test), in the β-arrestin-2 recruitment and 
GFP-β2-adrenoceptor internalization assays, respectively. 
To determine the kinetics of the onset of cAMP accumulation, β-arrestin-2 recruitment and 
GFP-β2-adrenoceptor internalization, cells were stimulated with concentrations of ligands 
that gave an equi-effective response to an EC80 concentration of isoprenaline. For cAMP 
accumulation, there was a slight lag between compound addition and complementation of the 
GloSensor-luciferase enzyme, therefore area under the curve was calculated for the first 10 
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minutes of stimulation. Using this method, we determined that C26 was significantly slower 
than adrenaline and isoprenaline for the accumulation of cAMP (P = 0.007, one-way 
ANOVA followed by Bonferroni post-test). Mean AUC were 563 ± 25.6, 438 ± 20.8 and 569 
± 27.1 for adrenaline, C26 and isoprenaline, respectively. In addition, when these 
experiments were repeated in the presence of the phosphodiesterase (PDE) inhibitor rolipram, 
the increase in cAMP mediated by C26 was sustained for longer than either isoprenaline or 
adrenaline (figure 3b). Adrenaline and isoprenaline also recruited β-arrestin-2 and 
internalized the GFP-β2-adrenoceptor at similar rates (figure 3c, d), with maximal levels 
being reached at approximately 2 hr after treatment. In contrast, C26 recruited β-arrestin-2 at 
a significantly slower rate than isoprenaline and adrenaline (P = 0.012, one-way ANOVA 
followed by Bonferroni post-test), as the mean t½ values of onset of β-arrestin-2 recruitment 
were determined to be 0.78 ± 0.13, 0.30 ± 0.06 and 0.31 ± 0.04 hr for C26, isoprenaline and 
adrenaline, respectively. The slower rate for C26 resulted in levels of β-arrestin-2 recruitment 
increasing up to 4 hr agonist incubation, where the intrinsic activity was determined to be 126 
± 3.52 % of the maximal isoprenaline response. In addition, C26 internalized the GFP-β2 
adrenoceptor at a slower rate than isoprenaline and adrenaline (P < 0.0001, one-way ANOVA 
followed by Bonferroni post-test). The mean t½ values of internalization were determined to 
be 0.78 ± 0.04, 0.37 ± 0.02, and 0.34 ± 0.01 hr for C26, isoprenaline and adrenaline, 
respectively. 
Binding and kinetics of C26  
As C26 demonstrated slower functional kinetics than either adrenaline or isoprenaline, but 
resulted in greater intrinsic activity over time, we investigated the binding kinetics of these 
compounds to determine if dissociation rates were contributing to this effect.  
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Isoprenaline and C26 were able to produce concentration-dependent inhibition of [3H]-DHA 
binding in CHO-β2 cell membranes (figure 4a, b). In the case of C26 a mean pKi of 9.81 ± 
0.09 was calculated, which is consistent with the mean pKi (9.78 ± 0.14) determined from 
studies by Beattie et al., (2010) using [3H]-CGP12177A and membranes prepared from sf9 
cells expressing human β2 adrenoceptor. As G proteins stabilise the high affinity 
conformation of the receptor, we also investigated the effect of including GTPγS in these 
assays to uncouple pre-bound receptor-G protein complexes and reveal the low affinity site. 
Using this approach, we showed that for isoprenaline (figure 4a), there was a shift from a 
two-site curve fit in the absence of GTPγS (mean pKi values of 8.84 ± 0.45 and 6.55 ± 0.15 
for high and low affinity sites, respectively), to a single-site fit in the presence of  GTPγS 
(mean pKi 6.59 ± 0.11, P = 0.003). In contrast, there was no shift in the inhibition of [3H]-
DHA binding by C26 when performed in the presence of GTPγS (figure 4b). This is similar 
to the data produced for the antagonist propranolol (figure 4c) where the pKi in the absence of 
GTPγS was determined to be 9.14 ± 0.30 and there was no shift in the curve in the presence 
of GTPγS.  
The kinetic parameters for C26 were then determined indirectly by monitoring how the 
association rate of [3H]-DHA was altered in the presence of increasing concentrations of C26 
(as described in Sykes & Charlton, 2010). Using this method (figure 4d), the kon and koff 
values were determined to be 3.70 ± 0.47 x108 (M-1 min-1) and 0.0212 ± 0.003 (min-1), 
respectively. In addition, the time taken for half of the bound C26 molecules to dissociate 
from the receptor (t½) was calculated to be 32.7 min.  
Duration of action of C26  
As C26 displays very slow receptor kinetics, we postulated this would also lead to persistent 
signalling and a long duration of action. To test this hypothesis, we monitored the retention of 
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receptors in intracellular vesicles and the relaxation effect of C26 on electrical field-induced 
contraction of isolated guinea pig tracheal strips following agonist washout. 
Using the GFP-β2 internalization assay, which is readily reversible, equi-effective 
concentrations of isoprenaline, C26 and adrenaline were incubated with U2OS GFP-β2 cells 
for 2 hr. After this time the cells were washed and bathed in assay buffer whilst the level of β2 
internalization was monitored over time. The amount of internalized receptors produced by 
isoprenaline and adrenaline began to decrease around 15 min after agonist washout, and 
continued to decrease steadily until baseline levels were achieved within 2 hr post agonist 
washout. In contrast, even at 4 hr post agonist washout, C26 held ~80 % of internalized 
receptors inside the cell and the rate of decline of internalized vesicles was very slow (figure 
5a). Estimated mean t½ values representing the loss of GFP-β2 vesicles from within U2OS 
cells were determined to be 44.2 ± 3.4, 1229 ± 289 and 40.0 ± 8.1 min for isoprenaline, C26 
and adrenaline, respectively (span fixed to 100 %).  
Following this, we assessed the duration of the relaxant effects of C26 in isolated guinea pig 
tracheal strips after 30 minute incubation with ligand. C26 was able to maximally inhibit the 
contraction of electrical field-induced contraction of isolated guinea pig tracheal strips (figure 
5b), with pEC50 of 10.37 ± 0.04. The onset and duration of action of C26 were derived using 
the concentration closest to the pEC50 value, in this case 30 pM. At this concentration the 
onset of action of C26 was determined to be 5.2 ± 0.4 hr and the duration of action of more 
than 12 hr (figure 5c).  
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Discussion 
In this study we have investigated the kinetics of binding and signalling of C26, a novel super 
agonist at the β2 adrenoceptor. The signalling properties of C26 were explored in three 
different functional assays, cAMP accumulation, β-arrestin-2 recruitment and receptor 
internalization. At all three levels of receptor signalling, C26 produced responses greater than 
the endogenous agonist adrenaline and the previously described full agonist isoprenaline, 
leading to its classification as a super agonist based on its intrinsic activity. In this way, C26 
shares properties with other synthetic ligands that have been shown to have higher intrinsic 
activity than their respective endogenous ligands, such as the non-peptide growth hormone 
secretagogue MK-677 (Bennett et al., 2009; Holst et al., 2005) and the thyrotropin-releasing 
hormone  analogue R-Des-TRH (Engel et al., 2006). 
In addition to monitoring the intrinsic activity of C26, we also investigated its kinetics in the 
signalling assays. We have previously demonstrated a correlation between high efficacy 
agonists and an increased rate of cAMP accumulation (Rosethorne et al., 2010), which would 
predict a faster onset of action for C26 than for either adrenaline or isoprenaline based on 
their relative intrinsic activities. However, we found the opposite was the case, such that C26 
produced the slowest rate of cAMP accumulation, β-arrestin-2 recruitment and receptor 
internalization. Maximal levels of cAMP accumulation were achieved 2-3 minutes after 
adrenaline and isoprenaline reached peak cAMP accumulation, and maximal levels of C26-
mediated β-arrestin-2 recruitment and receptor internalization were only achieved after at 
least 4 hr treatment as opposed to 2 hr with adrenaline and isoprenaline. Using kinetic 
radioligand binding assays we demonstrated that C26 has a half-life of 32.7 min at 37°C. 
Compared to isoprenaline and adrenaline (0.23 and 0.14 min, respectively) this represents the 
slowest dissociation rate we have observed for any β2 adrenoceptor agonist tested to date 
(Sykes & Charlton, 2012). As C26 demonstrates slow dissociation from the β2 adrenoceptor, 
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it is likely that this compound will also be slow to reach equilibrium, thus delaying its onset 
of action. This is supported by the steepness of the Hill slope for C26, which often occurs 
under non-equilibrium conditions. We have repeated these experiments in 10-fold the assay 
volume (data not shown) to eliminate the possibility that the steep slope is due to ligand 
depletion at the lower concentrations of C26 (Carter et al., 2007). The slow binding kinetics 
of C26 translated into a slow onset and long duration of action, with C26 inhibition of 
electrically stimulated contraction of guinea pig tracheal strips being sustained for at least 12 
hours after agonist wash-out. We also observed that in the presence of a PDE inhibitor the 
cAMP generated by C26 was sustained for longer than either adrenaline or isoprenaline, 
which may suggest that C26 continues to promote cAMP generation over longer periods. The 
slow kinetic binding and signalling appear to be properties unique to C26, as other high 
affinity, long acting beta2 agonists have been shown to rapidly dissociate from the receptor 
(Sykes and Charlton, 2012). It is believed that for many of the LABAs such as salmeterol, the 
high lipophilicity of these compounds contributes to their long duration of action (Anderson 
et al., 1994). In the case of C26, it is likely that its slow dissociation from the receptor 
provides a significant contribution, as it has a longer duration of action than would be 
predicted from its lipophilicity (calculated LogP of C26 = 2.42 ± 0.54; salmeterol = 3.90 ± 
0.49; from ALOGPS v2.1), although we can’t rule out a contribution of tissue retention. The 
persistent internalization of GFP-β2 receptors caused by C26 even after agonist wash-out 
provides another potential factor that could be contributing to the long duration of action of 
C26. It has previously been thought that signal transduction mediated by GPCR is confined to 
the plasma membrane, and once receptors are phosphorylated and internalized these 
processes are switched off. However, recent evidence suggests that internalised receptors are 
capable of forming active ternary complex by accessing effectors from subcellular 
compartments, which contributes to the total cellular signalling. This has been demonstrated 
MOL #101253 
22 
 
for a range of receptors, including the parathyroid and thyroid-stimulating hormone receptors, 
as well as the S1P1 and β2 adrenoceptor (Calebiro et al., 2009; Ferrandon et al., 2009; 
Irannejad et al., 2013; Mullershausen et al., 2009). Indeed, slow dissociation kinetics have 
been linked to the ability of FTY720 to cause persistent internalization of the S1P1 receptor 
(Sykes et al., 2014). As such, the prolonged receptor internalisation caused by C26 may 
provide an additional mechanism of long duration of action at the β2 adrenoceptor, which 
may be further exploited by targeting drugs to intracellular compartments e.g. by 
incorporating physiochemical properties that facilitate ion trapping (Goldman et al., 2009). 
The continued signalling of certain agonists from internalized compartments may contribute 
to the overall magnitude of intracellular signalling as well as the duration of responses, which 
may underlie signalling bias by directing receptors to alternative pathways/compartments or 
degradation. C26 may therefore be a useful tool to study this phenomenon in more detail. 
A number of different approaches have been used to quantify agonist efficacy, ranging from 
simple calculations such as KA/EC50 or Emax.KA/EC50 (Strange, 2008), to more 
thermodynamically complete systems such as the cubic ternary complex model (Weiss et al., 
1996). However, it is more common to fit data with empirical mathematical models like the 
Operational model of agonism to quantify agonist efficacy (Black and Leff, 1983). This 
model has been used to describe super agonists that that are more efficient at transducing 
receptor binding events into a cellular response, such as iperoxo, which demonstrates supra-
physiological efficacy compared to acetylcholine at the muscarinic M2 acetylcholine receptor 
(Schrage et al., 2013). These models are of little use for C26, as both the KA/EC50 and 
Emax.KA/EC50 calculations predict a lower efficacy for this compound than either adrenaline 
or isoprenaline, despite its higher intrinsic activity (Table 2). The Operational model also 
struggles to correctly fit the data we have obtained with C26, either over-estimating the 
maximal response of adrenaline and isoprenaline relative to C26, or over-estimating the 
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potency based on the affinity entered into the equation. This may be because the affinity 
measured in this study is not an accurate representation of the “functional affinity” at a 
specific pathway, due to effector-dependent changes in receptor conformation (Kenakin and 
Christopoulos, 2013; Yan et al., 2008). Although efforts have been made to measure this 
using receptor-effector fusions (Rasmussen et al., 2011), it remains very difficult to 
accurately measure functional affinity of high full (or super) agonists.  
Our data indicate that C26 was insensitive to guanine-nucleotides suggesting it either does 
not stabilize many receptors in the classical high-affinity state, or that it has equal affinity for 
the high and low affinity states of the receptor, as has been reported previously for a number 
of different high affinity GPCR agonists (Childers et al., 1993; Roberts et al., 2004; 
Schneider et al., 2009; Vanhauwe et al., 1999). One explanation for this is that ligands that do 
not affect the overall affinity of the receptor for the G protein, but rather accelerate guanyl 
nucleotides binding and dissociation will be functionally active, but unable to discriminate 
two receptor states in binding studies (Waelbroeck et al., 1997). This can be likened to the 
allosteric ternary complex model (figure 6), where the G protein is defined as an allosteric 
modulator of ligand-receptor interactions (Leach et al., 2007). Using this model, C26 yields 
an α value of 1.3 (α = KLow / KHigh; data taken from figure 4b), which indicates that the 
presence of the G protein on the receptor had no effect on the affinity of C26 (KLow ≈ KHigh) 
(Christopoulos and Kenakin, 2002). In contrast, the presence of the G protein had a positive 
allosteric effect on the binding of isoprenaline to the β2 adrenoceptor, resulting in α =194 
(KLow > KHigh; data taken from figure 4a). Despite having an α value close to 1, C26 has 
higher intrinsic activity than isoprenaline, suggesting its effect is to enhance the ability of the 
receptor to activate the effector (β > 1), for example the ability to accelerate GDP-GTP 
exchange (Waelbroeck et al., 1997; Sykes et al, 2009).  
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In conclusion, we have fully characterized C26, a kinetically-driven super agonist at the 
human β2 adrenoceptor that displays higher intrinsic activity than either the endogenous 
agonist adrenaline, or the full agonist isoprenaline. We have demonstrated that this compound 
displays extremely slow receptor dissociation kinetics for an agonist, and propose that this 
contributes to the increased intrinsic activity of C26 over time. This can most easily be 
visualised by observing the relative intrinsic activity of an EC80 concentration (determined 
after 8 min) of each agonist over time. In this model C26 has a lower intrinsic activity at the 
early time points where it appears partial relative to adrenaline, versus the later time point 
where it has greater intrinsic activity than adrenaline (figure 7). This highlights the need to 
consider the temporal aspects of agonist binding and signalling when characterising ligands 
as super agonists. 
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Figure Legends 
Figure 1 Chemical structure of C26 
Figure 2 Concentration-response curves for (a) cAMP accumulation in A341 cells, (b) β-
arrestin-2 recruitment in CHO-β2 cells and (c) GFP-β2 internalization in U2OS cells using 
adrenaline, C26 and isoprenaline. Data are normalised to the 2 hr isoprenaline response, and 
expressed as means ± S.E.M. for 3-8 independent experiments, run in duplicate. 
Figure 3 Time courses of cAMP accumulation in A431 cells (a), β-arrestin-2 recruitment in 
CHO-β2 cells (b) and GFP-β2 internalization in U2OS cells (c) using equi-effective 
concentrations of adrenaline, C26 and isoprenaline, equivalent to an EC80 concentration of 
isoprenaline taken from GloSensor data (not shown), or data in figure 2 (b) and (c), 
respectively. Data are expressed as means ± S.E.M. for 3 (arrestin and internalization) or 4 
(cAMP) independent experiments, run in duplicate. Statistical significance was determined 
using one-way ANOVA followed by Bonferroni multiple comparisons equation using 
GraphPad Prism. 
Figure 4 Inhibition of [3H]-DHA binding data in CHO-β2-adrenoceptor membranes using (a) 
isoprenaline, (b) C26 and (c) propranolol, in the absence or presence of 100 µM GTPγS. d) 
[3H]-DHA competition kinetics curves in CHO-β2-adrenoceptor membranes in the presence 
of either 0, 3-fold Ki, 10-fold Ki or 30-fold Ki C26. Data were fitted to the equations described 
in the methods to calculate kon and koff values for unlabelled agonists. Data in a-c are 
normalised to % receptors bound. All graphs show representative data (mean of duplicate or 
triplicate determinations ± range) from 3 independent experiments. 
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Figure 5 a) Rate of loss of GFP-β2 internalized receptors in U2OS cells following washout of 
agonist. Equi-effective concentrations of adrenaline, C26 and isoprenaline were used, 
equivalent to an EC80 concentration of isoprenaline taken from data in figure 2 (c). Data are 
expressed as means ± S.E.M. for 3 independent experiments. b) Concentration-response for 
the inhibition of electrical-field induced contraction by C26 in isolated Guinea-pig tracheal 
strips. c) Time course of inhibition of electrical-field induced contraction in isolated Guinea-
pig tracheal strips using a range of different concentrations of C26. Data are expressed as 
means ± S.E.M from 3-5 independent experiments. 
Figure 6 Allosteric ternary complex model between ligand (A), receptor (R) and G protein 
(G). Model adapted from Leach et al., (2007). 
Figure 7 Relative intrinsic activities of C26 and adrenaline for cAMP accumulation after 
incubation with EC80 concentrations of each agonist. Data are normalised to the maximal 
adrenaline response (8 minutes), and expressed as means ± S.E.M. for 4 independent 
experiments, run in duplicate. Statistical significance was determined using an unpaired t-test 
(P < 0.05) at 3 versus 10 minutes. 
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Table 1 Potency and intrinsic activity values for β2 adrenoceptor agonists in different functional assays.  
Potency and intrinsic activity values for adrenaline, C26 and isoprenaline in cAMP accumulation in A431 cells,  β-arrestin recruitment 
in CHO-β2 cells and internalization of GFP-β2 in U2OS cells. Intrinsic activity was calculated as a percentage of the maximal 
isoprenaline response. Data are expressed as means ± S.E.M. for 3-8 independent experiments, as indicated in brackets.  
* p < 0.05; ** p < 0.01; One-way ANOVA followed by Bonferroni’s multiple comparisons relative to adrenaline. 
 
 cAMP accumulation in A431 cells β-arrestin recruitment in CHO-β2 cells Internalization of GFP-β2 in U2OS cells 
Agonist pEC50 (n) Intrinsic activity pEC50 (n) Intrinsic activity pEC50 (n) Intrinsic activity 
Adrenaline 7.5 ± 0.13 (5) 91.4 ± 5.7 7.5 ± 0.06 (3) 100.9 ± 1.0 7.24 ± 0.14 (4) 95.3 ± 4.9 
C26 10.2 ± 0.07 (5) 117.8 ± 7.6* 9.76 ± 0.05 (6) 118.5 ± 6.7* 9.87 ± 0.08 (4) 121.0 ± 6.9** 
Isoprenaline 7.8 ± 0.06 (3) 102.4 ± 1.3 8.42 ± 0.05 (6) 100.5 ± 1.2 7.65 ± 0.06 (8) 99.0 ± 1.85 
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Table 2 Efficacy calculations for adrenaline, C26 and isoprenaline 
 cAMP accumulation in A431 cells β-arrestin recruitment in CHO-β2 cells Internalization of GFP-β2 in U2OS cells 
 KA/EC50 Emax.KA/EC50 KA/EC50 Emax.KA/EC50 KA/EC50 Emax.KA/EC50 
Adrenaline 44.7 4083 44.7 4507 24.5 2339 
C26 1.05 123 0.38 45.1 0.49 59.3 
Isoprenaline 8.13 832 33.9 3405 5.75 570 
 







